Georgina Lorente-Meneses

Hexagon Place, Shire Park, Falcon Way
Welwyn Garden City, ENG AL71TW, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

In silico & in vitro approaches suggest osteoclastogenesis induction underlying fractures in Entrectinib-treated children.

In silico & in vitro approaches suggest osteoclastogenesis induction underlying fractures in Entrectinib-treated children.

Journal: Archives of toxicology

Published: April 01, 2025

Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics.

Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics.

Journal: Clinical pharmacokinetics

Published: December 04, 2024

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 23, 2024

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co-Administered with CYP3A4 Inhibitors.

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co-Administered with CYP3A4 Inhibitors.

Journal: Clinical pharmacology and therapeutics

Published: April 02, 2024

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.

Journal: Cancer chemotherapy and pharmacology

Published: August 04, 2022

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

Journal: Neuro-oncology

Published: April 08, 2022

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer

Published: March 08, 2022

Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.

Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.

Journal: Cancer chemotherapy and pharmacology

Published: October 01, 2021

Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.

Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.

Journal: European journal of drug metabolism and pharmacokinetics

Published: August 17, 2021

Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.

Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.

Journal: Cancer chemotherapy and pharmacology

Published: May 17, 2021

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).

Journal: Investigational new drugs

Published: April 15, 2021

Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.

Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.

Journal: Investigational new drugs

Published: October 30, 2020

Showing 1-12 of 30

Last Updated: 09/26/2026